Josee-Lyne Ethier

TL;DR: Oncologists ranked patient- and family-related factors as the most important barriers to GOC discussions, while clinicians’ self-identified difficulty estimating prognosis and uncertainty regarding treatment benefits were also considered important.

TL;DR: The role of niraparib in the treatment of EOC is focused on, leading to the first polyadenosine diphosphate-ribose polymerase inhibitors approval by the US FDA in this setting.

TL;DR: In this article, a review of neoadjuvant and adjuvant therapy options for women with newly diagnosed stage II-IV ovarian cancer was performed using MEDLINE, EMBASE, and Cochrane Library.

TL;DR: In this paper, the authors describe practice patterns and outcomes associated with pertuzumab and T-DM1 in routine clinical practice, and identify factors associated with OS using a Cox proportional hazard model.

TL;DR: In this article, the authors conducted a scoping review and developed a model useful to guide clinical discussions and/or intervention to support GC survivors in transition out of primary cancer treatment, including physical needs, sexuality related concerns, altered self-image, psychological wellbeing, social support needs, supporting the return to work, and healthcare challenges and preferences.